Published in Mol Microbiol on August 01, 2002
Yersinia type III secretion: send in the effectors. J Cell Biol (2002) 3.04
Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen). Infect Immun (2003) 2.20
CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia (2006) 2.05
Requirement of the Yersinia pseudotuberculosis effectors YopH and YopE in colonization and persistence in intestinal and lymph tissues. Infect Immun (2003) 1.64
The adaptor molecules LAT and SLP-76 are specifically targeted by Yersinia to inhibit T cell activation. J Exp Med (2005) 1.15
Transcriptomic and innate immune responses to Yersinia pestis in the lymph node during bubonic plague. Infect Immun (2010) 1.05
Adi3 is a Pdk1-interacting AGC kinase that negatively regulates plant cell death. EMBO J (2005) 1.01
Intranasal inoculation of mice with Yersinia pseudotuberculosis causes a lethal lung infection that is dependent on Yersinia outer proteins and PhoP. Infect Immun (2006) 1.01
The proinflammatory response induced by wild-type Yersinia pseudotuberculosis infection inhibits survival of yop mutants in the gastrointestinal tract and Peyer's patches. Infect Immun (2006) 0.95
GSK3β and the control of infectious bacterial diseases. Trends Microbiol (2014) 0.94
Early apoptosis of macrophages modulated by injection of Yersinia pestis YopK promotes progression of primary pneumonic plague. PLoS Pathog (2013) 0.91
YopH inhibits early pro-inflammatory cytokine responses during plague pneumonia. BMC Immunol (2010) 0.91
Modulation and utilization of host cell phosphoinositides by Salmonella spp. Infect Immun (2004) 0.90
Yersinia pseudotuberculosis anti-inflammatory components reduce trinitrobenzene sulfonic acid-induced colitis in the mouse. Infect Immun (2004) 0.86
Role of IFN-gamma and IL-6 in a protective immune response to Yersinia enterocolitica in mice. BMC Microbiol (2008) 0.84
Comparative Global Gene Expression Profiles of Wild-Type Yersinia pestis CO92 and Its Braun Lipoprotein Mutant at Flea and Human Body Temperatures. Comp Funct Genomics (2010) 0.84
Pathogenic Bacterial Proteins and their Anti-Inflammatory Effects in the Eukaryotic Host. Antiinflamm Antiallergy Agents Med Chem (2009) 0.82
Circumventing Y. pestis Virulence by Early Recruitment of Neutrophils to the Lungs during Pneumonic Plague. PLoS Pathog (2015) 0.82
Characterization of new substrates targeted by Yersinia tyrosine phosphatase YopH. PLoS One (2009) 0.78
Host response during Yersinia pestis infection of human bronchial epithelial cells involves negative regulation of autophagy and suggests a modulation of survival-related and cellular growth pathways. Front Microbiol (2015) 0.78
c-KIT signaling is targeted by pathogenic Yersinia to suppress the host immune response. BMC Microbiol (2013) 0.78
Attenuation of the phosphatidylinositol 3-kinase/Akt signaling pathway by Porphyromonas gingivalis gingipains RgpA, RgpB, and Kgp. J Biol Chem (2015) 0.77
Yersinia type III effectors perturb host innate immune responses. World J Biol Chem (2016) 0.77
Bacillus cereus Certhrax ADP-ribosylates vinculin to disrupt focal adhesion complexes and cell adhesion. J Biol Chem (2014) 0.76
Yersinia enterocolitica YopH-deficient Strain Activates Neutrophil Recruitment to Peyer's patches Promoting Clearance of the Virulent Strain. Infect Immun (2016) 0.75
The tomato cell death suppressor Adi3 is restricted to the endosomal system in response to the Pseudomonas syringae effector protein AvrPto. PLoS One (2014) 0.75
Exploring Oxidovanadium(IV) Complexes as YopH Inhibitors: Mechanism of Action and Modeling Studies. ACS Med Chem Lett (2015) 0.75
Yersinia pseudotuberculosis supports Th17 differentiation and limits de novo regulatory T cell induction by directly interfering with T cell receptor signaling. Cell Mol Life Sci (2017) 0.75
Induction of type I interferon through a non-canonical Toll-like receptor 7 pathway during Yersinia pestis infection. Infect Immun (2017) 0.75
Human T cell responses against melanoma. Annu Rev Immunol (2006) 4.99
The V-antigen of Yersinia forms a distinct structure at the tip of injectisome needles. Science (2005) 2.90
The needle length of bacterial injectisomes is determined by a molecular ruler. Science (2003) 2.27
Type III secretion: more systems than you think. Physiology (Bethesda) (2005) 2.26
The bacterial injection kit: type III secretion systems. Ann Med (2005) 2.23
An antigenic peptide produced by peptide splicing in the proteasome. Science (2004) 2.20
The N-glycan glycoprotein deglycosylation complex (Gpd) from Capnocytophaga canimorsus deglycosylates human IgG. PLoS Pathog (2011) 2.09
Role of Yops and adhesins in resistance of Yersinia enterocolitica to phagocytosis. Infect Immun (2002) 1.97
Bacterial injectisomes: needle length does matter. Science (2005) 1.86
The multitalented type III chaperones: all you can do with 15 kDa. FEMS Microbiol Lett (2003) 1.83
Targeting Rac1 by the Yersinia effector protein YopE inhibits caspase-1-mediated maturation and release of interleukin-1beta. J Biol Chem (2004) 1.70
Protective anti-V antibodies inhibit Pseudomonas and Yersinia translocon assembly within host membranes. J Infect Dis (2005) 1.67
Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med (2003) 1.59
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. J Immunol (2007) 1.56
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer (2005) 1.55
Structure of the dodecameric Yersinia enterocolitica secretin YscC and its trypsin-resistant core. Structure (2013) 1.49
Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity (2008) 1.48
Characterization of the ysa pathogenicity locus in the chromosome of Yersinia enterocolitica and phylogeny analysis of type III secretion systems. J Mol Evol (2002) 1.45
Function and molecular architecture of the Yersinia injectisome tip complex. Mol Microbiol (2007) 1.45
YscU recognizes translocators as export substrates of the Yersinia injectisome. EMBO J (2007) 1.44
Deciphering the assembly of the Yersinia type III secretion injectisome. EMBO J (2010) 1.40
Genetic analysis of the formation of the Ysc-Yop translocation pore in macrophages by Yersinia enterocolitica: role of LcrV, YscF and YopN. Microb Pathog (2003) 1.39
Type III secretion: the bacteria-eukaryotic cell express. FEMS Microbiol Lett (2005) 1.36
Theileria parva candidate vaccine antigens recognized by immune bovine cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (2006) 1.36
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol (2005) 1.30
Type III secretion translocation pores of Yersinia enterocolitica trigger maturation and release of pro-inflammatory IL-1beta. Cell Microbiol (2007) 1.26
Characterization of a Type III secretion substrate specificity switch (T3S4) domain in YscP from Yersinia enterocolitica. Mol Microbiol (2005) 1.25
A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res (2010) 1.25
SycE allows secretion of YopE-DHFR hybrids by the Yersinia enterocolitica type III Ysc system. Mol Microbiol (2002) 1.25
Role of the pilot protein YscW in the biogenesis of the YscC secretin in Yersinia enterocolitica. J Bacteriol (2004) 1.24
In situ structural analysis of the Yersinia enterocolitica injectisome. Elife (2013) 1.24
Comparison of stable human Treg and Th clones by transcriptional profiling. Eur J Immunol (2009) 1.23
The discovery of SycO highlights a new function for type III secretion effector chaperones. EMBO J (2006) 1.23
Capnocytophaga canimorsus: a human pathogen feeding at the surface of epithelial cells and phagocytes. PLoS Pathog (2008) 1.22
Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci U S A (2004) 1.21
Structure of the Yersinia enterocolitica type III secretion translocator chaperone SycD. J Mol Biol (2007) 1.20
Escape from immune surveillance by Capnocytophaga canimorsus. J Infect Dis (2006) 1.20
Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun (2013) 1.19
T-cell responses of vaccinated cancer patients. Curr Opin Immunol (2003) 1.18
Up-regulation of the Yersinia enterocolitica yop regulon by deletion of the flagellum master operon flhDC. J Bacteriol (2002) 1.17
Type III secretion: a secretory pathway serving both motility and virulence (review). Mol Membr Biol (2005) 1.16
The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res (2009) 1.14
Effect of low- and high-virulence Yersinia enterocolitica strains on the inflammatory response of human umbilical vein endothelial cells. Infect Immun (2002) 1.13
Resistance of Capnocytophaga canimorsus to killing by human complement and polymorphonuclear leukocytes. Infect Immun (2009) 1.11
Identification of a nuclear targeting signal in YopM from Yersinia spp. Microb Pathog (2004) 1.10
Prevalence of Capnocytophaga canimorsus in dogs and occurrence of potential virulence factors. Microbes Infect (2009) 1.08
Secretion of YscP from Yersinia enterocolitica is essential to control the length of the injectisome needle but not to change the type III secretion substrate specificity. Mol Microbiol (2005) 1.07
The YfiBNR signal transduction mechanism reveals novel targets for the evolution of persistent Pseudomonas aeruginosa in cystic fibrosis airways. PLoS Pathog (2012) 1.07
The assembly of the export apparatus (YscR,S,T,U,V) of the Yersinia type III secretion apparatus occurs independently of other structural components and involves the formation of an YscV oligomer. Mol Microbiol (2011) 1.05
Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. Mol Ther (2012) 1.05
Regulation of mRNA expression in macrophages after Yersinia enterocolitica infection. Role of different Yop effectors. J Biol Chem (2002) 1.05
The helical content of the YscP molecular ruler determines the length of the Yersinia injectisome. Mol Microbiol (2008) 1.04
Characterization of the fine specificity of bovine CD8 T-cell responses to defined antigens from the protozoan parasite Theileria parva. Infect Immun (2007) 1.04
CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation. Blood (2006) 1.04
Capnocytophaga canimorsus resists phagocytosis by macrophages and blocks the ability of macrophages to kill other bacteria. Immunobiology (2008) 1.03
Complete genome sequence of the dog commensal and human pathogen Capnocytophaga canimorsus strain 5. J Bacteriol (2011) 1.01
Structure of the type III secretion recognition protein YscU from Yersinia enterocolitica. J Mol Biol (2008) 1.01
Identification of substrates and chaperone from the Yersinia enterocolitica 1B Ysa type III secretion system. Infect Immun (2003) 1.01
The genome and surface proteome of Capnocytophaga canimorsus reveal a key role of glycan foraging systems in host glycoproteins deglycosylation. Mol Microbiol (2011) 1.00
Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res (2009) 1.00
Length control of the injectisome needle requires only one molecule of Yop secretion protein P (YscP). Proc Natl Acad Sci U S A (2010) 1.00
Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J Immunol (2008) 1.00
Genetic tools for studying Capnocytophaga canimorsus. Appl Environ Microbiol (2008) 0.99
Loss of effector function of human cytolytic T lymphocytes is accompanied by major alterations in N- and O-glycosylation. J Biol Chem (2012) 0.98
The lipopolysaccharide from Capnocytophaga canimorsus reveals an unexpected role of the core-oligosaccharide in MD-2 binding. PLoS Pathog (2012) 0.96
The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J Exp Med (2002) 0.96
Translocators YopB and YopD from Yersinia enterocolitica form a multimeric integral membrane complex in eukaryotic cell membranes. J Bacteriol (2011) 0.95
Oligomeric coiled-coil adhesin YadA is a double-edged sword. PLoS One (2010) 0.94
Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J Immunol (2004) 0.91
Frequent DNA hypomethylation of human juxtacentromeric BAGE loci in cancer. Genes Chromosomes Cancer (2005) 0.91
Sequestering of Rac by the Yersinia effector YopO blocks Fcgamma receptor-mediated phagocytosis. J Biol Chem (2009) 0.91
Interleukins 1alpha and 1beta secreted by some melanoma cell lines strongly reduce expression of MITF-M and melanocyte differentiation antigens. Int J Cancer (2010) 0.90
Assembly of the Yersinia injectisome: the missing pieces. Mol Microbiol (2012) 0.90
A novel strategy for the identification of antigens that are recognised by bovine MHC class I restricted cytotoxic T cells in a protozoan infection using reverse vaccinology. Immunome Res (2007) 0.89
The Type III secretion system of Gram-negative bacteria: a potential therapeutic target? Expert Opin Ther Targets (2001) 0.89
Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy. J Immunol (2004) 0.87
A short treatment with galactomannan GM-CT-01 corrects the functions of freshly isolated human tumor-infiltrating lymphocytes. Clin Cancer Res (2014) 0.87
A reversible functional defect of CD8+ T lymphocytes involving loss of tetramer labeling. Eur J Immunol (2002) 0.87
Crystal structure of Yersinia enterocolitica type III secretion chaperone SycT. Protein Sci (2005) 0.86
Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family. Cancer Immunol Immunother (2006) 0.86
Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein. J Immunol (2005) 0.86
IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma. PLoS One (2012) 0.84
A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors. Cancer Immunol Immunother (2005) 0.83
DNA sequence and analysis of the pYVa127/90 virulence plasmid of Yersinia enterocolitica strain A127/90. Res Microbiol (2003) 0.83
New BAGE (B melanoma antigen) genes mapping to the juxtacentromeric regions of human chromosomes 13 and 21 have a cancer/testis expression profile. Eur J Hum Genet (2002) 0.82
A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells. Eur J Immunol (2005) 0.82
A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells. Cancer Immunol Immunother (2005) 0.81
Tumor-reactive CD4+ T cell responses to the melanoma-associated chondroitin sulphate proteoglycan in melanoma patients and healthy individuals in the absence of autoimmunity. J Immunol (2007) 0.80
A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16. Cancer Immun (2003) 0.79
Inefficient exogenous loading of a tapasin-dependent peptide onto HLA-B*44:02 can be improved by acid treatment or fixation of target cells. Eur J Immunol (2012) 0.79
Yersinia enterocolitica type III secretion injectisomes form regularly spaced clusters, which incorporate new machines upon activation. Mol Microbiol (2015) 0.79
A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A24 carcinoma cells. Cancer Immunol Immunother (2005) 0.76
Correction: The N-glycan Glycoprotein Deglycosylation Complex (Gpd) from Capnocytophaga canimorsus Deglycosylates Human IgG. PLoS Pathog (2015) 0.75
Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy. J Immunother (2016) 0.75
NMR-based structural analysis of the complete rough-type lipopolysaccharide isolated from Capnocytophaga canimorsus. J Biol Chem (2015) 0.75